Published in Cancer Weekly, December 16th, 2003
Nanoparticle albumin-bound (nab) technology, for the first time, combines a physiologically interactive human protein, albumin, with an active pharmaceutical agent, resulting in compounds which are free of toxicities associated with the use of solvent-based formulations. The compound closest to commercialization is nab...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.